Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution
Open Access
- 28 June 2011
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 437 (2) , 185-197
Abstract
Inflammation when unchecked is associated with many prevalent disorders such as the classic inflammatory diseases arthritis and periodontal disease, as well as the more recent additions that include diabetes and cardiovascular maladies. Hence mechanisms to curtail the inflammatory response and promote catabasis are of immense interest. In recent years, evidence has prompted a paradigm shift whereby the resolution of acute inflammation is a biochemically active process regulated in part by endogenous PUFA (polyunsaturated fatty acid)-derived autacoids. Among these are a novel genus of SPMs (specialized proresolving mediators) that comprise novel families of mediators including lipoxins, resolvins, protectins and maresins. SPMs have distinct structures and act via specific G-protein seven transmembrane receptors that signal intracellular events on selective cellular targets activating proresolving programmes while countering pro-inflammatory signals. An appreciation of these endogenous pathways and mediators that control timely resolution opened a new terrain for therapeutic approaches targeted at stimulating resolution of local inflammation. In the present review, we provide an overview of the biosynthesis and actions of resolvin E1, underscoring its protective role in vascular systems and regulating platelet responses. We also give an overview of newly described resolution circuitry whereby resolvins govern miRNAs (microRNAs), and transcription factors that counter-regulate pro-inflammatory chemokines, cytokines and lipid mediators.Keywords
This publication has 136 references indexed in Scilit:
- The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejectionProstaglandins, Leukotrienes and Essential Fatty Acids, 2011
- Specialized pro-resolving lipid mediators in the inflammatory response: An updateBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actionsNature Medicine, 2010
- Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium–induced colitisInflammatory Bowel Diseases, 2010
- Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsisNature, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammationNature Immunology, 2008
- Resolvin E1 and protectin D1 activate inflammation-resolution programmesNature, 2007
- Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expressionNature Immunology, 2006